Last week, Mylan announced that its share earnings were stronger than expected. As a result, the company raised its outlook for the year. The company’s 2015 adjusted per-share earnings guidance previously sat at $4.00-$4.30 to $4.15-$4.35. Mylan also continues to acquire Perrigo, a move that they have sought after for most of the year. Mylan’s potential acquisition of Perrigo would help the company avoid a takeover from Teva. Perrigo has resisted Mylan’s overtures.